EMA Works On Definition To Support Similarity Assessments For Orphan Drugs

The European Medicines Agency is working on a definition for 'principal molecular structural features'- a term in the EU orphan drugs legislation for determining the similarity between a drug in the pre-authorization phase and a drug that has already received orphan designation or market authorization.